



NDA 206352/S-003
NDA 21567/S-038

**SUPPLEMENT APPROVAL /
FULFILLMENT OF POSTMARKETING
REQUIREMENT**

Bristol-Myers Squibb Company
Attention: Lisa Percival
Director, Global Regulatory Strategy
5 Research Parkway, Mailstop 2CW-506
Wallingford, CT 06492

Dear Ms. Percival:

Please refer to your Supplemental New Drug Applications (sNDAs) dated and received March 27, 2015, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for REYATAZ[®] (atazanavir) oral powder, 50 mg per packet and REYATAZ[®] (atazanavir) capsules, 150 mg, 200 mg and 300 mg.

We acknowledge receipt of your amendments on the following dates:

**NDA 206352 / S-003
(atazanavir oral powder)**

April 10, 2015
April 23, 2015
April 28, 2015
May 8, 2015
June 9, 2015
June 25, 2015
July 7, 2015
August 3, 2015
August 26, 2015
September 15, 2015
September 22, 2015
September 23, 2015

**NDA 21567 / S-038
(atazanavir capsules)**

April 10, 2015
April 23, 2015
April 28, 2015
June 9, 2015
July 7, 2015
August 3, 2015
August 26, 2015
September 15, 2015
September 22, 2015
September 23, 2015

The Prior Approval Supplemental new drug application, NDA 206352/S-003, proposes to expand the use of REYATAZ[®] (atazanavir) oral powder, in combination with other antiviral agents, for treatment of HIV-1 infection in pediatric patients who are at least three (3) months of age and who weigh between five to less than ten kilograms (5 to < 10 kg). This submission intends to fulfill the post-marketing requirement, number 2153-1, under the Pediatric Research

Equity Act (PREA) and represents the final report to the Pediatric Written Request under the Best Pharmaceuticals for Children Act (BPCA). In addition this application provides for the use of REYATAZ[®] oral powder formulation in pediatric and adult patients weighing greater than 25 kilograms (>25 kg), who are unable to swallow capsules.

The Prior Approval Supplemental new drug application to NDA 21567/S-038 for REYATAZ[®] (atazanavir) capsules updates the shared labeling with the aforementioned expanded indication for REYATAZ[®] (atazanavir) oral powder. The shared labeling was voluntarily updated in accordance with the Pregnancy and Lactation Labeling Rule (PLLR) which went into effect on June 30, 2015.

APPROVAL & LABELING

We have completed our review of these supplemental applications. They are approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

WAIVER OF HIGHLIGHTS SECTION

Please note that we have previously granted a waiver of the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of prescribing information.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at. Content of labeling must be identical to the enclosed labeling (text for the package insert and text for the patient package insert), with the addition of any labeling changes in pending “Changes Being Effectuated” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.”

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy

should provide appropriate annotations, including supplement number(s) and annual report date(s).

CARTON AND IMMEDIATE CONTAINER LABELS

Submit final printed carton and immediate container labels that are identical to the carton and immediate-container labels submitted on March 27, 2015, as soon as they are available, but no more than 30 days after they are printed. Please submit these labels electronically according to the guidance for industry *Providing Regulatory Submissions in Electronic Format – Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (June 2008)*. Alternatively, you may submit 12 paper copies, with 6 of the copies individually mounted on heavy-weight paper or similar material. For administrative purposes, designate this submission “**Final Printed Carton and Container Labels for approved NDA 206352/S-003 and NDA 21567/S-038.**” Approval of this submission by FDA is not required before the labeling is used.

Marketing the product(s) with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

We reference your waiver, previously granted on July 6, 2004, waiving the pediatric study requirement for REYATAZ® (atazanavir) capsules (NDA 21567) for ages < 3 months because there is evidence strongly suggesting that the drug product would be unsafe in this pediatric age group due to the risk of kernicterus.

We note that you have fulfilled the pediatric studies requirement for all relevant pediatric age groups for these applications.

FULFILLMENT OF POSTMARKETING REQUIREMENT

This supplement (NDA 206352) was also submitted to fulfill the following PREA postmarketing requirement:

2153-1 Deferred pediatric study under PREA to evaluate atazanavir oral powder pharmacokinetics, safety and treatment response in HIV-1 infected pediatric patients 3 months and older who weigh 5 kg to less than 10 kg.

The approval of this supplement fulfills this postmarketing requirement.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit the following, in triplicate, (1) a cover letter requesting advisory comments, (2) the proposed materials in draft or mock-up form with annotated references, and (3) the package insert(s) to:

OPDP Regulatory Project Manager
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Prescription Drug Promotion (OPDP)
5901-B Ammendale Road
Beltsville, MD 20705-1266

Alternatively, you may submit a request for advisory comments electronically in eCTD format. For more information about submitting promotional materials in eCTD format, see the draft Guidance for Industry (available at:

<http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM443702.pdf>). You must submit final promotional materials and package insert(s),

accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at

<http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf>.

Information and Instructions for completing the form can be found at

<http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf>. For

more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see <http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm>.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Suzanne Strayhorn, Regulatory Project Manager, at (240) 402-4247.

Sincerely,

{See appended electronic signature page}

Debra Birnkrant, M.D.
Director
Division of Antiviral Products

NDA 206352/S-003
NDA 21567/S-038
Page 5

Office of Antimicrobial Products
Center for Drug Evaluation and Research

ENCLOSURE(S):
Content of Labeling
Carton and Container Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

JEFFREY S MURRAY
09/24/2015